What, how and who: Cost-effectiveness analyses of COVID-19 vaccination to inform key policies in Nigeria.

ABSTRACT: While safe and efficacious COVID-19 vaccines have achieved high coverage in high-income settings, roll-out remains slow in sub-Saharan Africa. By April 2022, Nigeria, a country of over 200 million people, had only distributed 34 million doses. To ensure the optimal use of health resources, cost-effectiveness analyses can inform key policy questions in the health technology assessment process. We carried out several cost-effectiveness analyses exploring different COVID-19 vaccination scenarios in Nigeria. In consultation with Nigerian stakeholders, we addressed three key questions: what vaccines to buy, how to deliver them and what age groups to target. We combined an epidemiological model of virus transmission parameterised with Nigeria specific data with a costing model that incorporated

SUBMITTER: Ruiz FJ 

PROVIDER: S-EPMC10032534 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature